June 1 (Reuters) - Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease.
from Reuters: New Issues News http://ift.tt/1TXwu9O
Tidak ada komentar:
Posting Komentar